Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 8/20 | 0.52 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL161936 | 0.86 | ENPP2 (0.50) | SMN1; SMN2ALDH1A1ENPP2MAPTPRKCZ | |
| SCHEMBL163919 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1RAB9AGAAMAPT | |
| SCHEMBL14551140 | 0.79 | ALDH1A1 (0.68) | SMN1; SMN2ALDH1A1RAB9AGAAMAPT | |
| SCHEMBL163086 | 0.78 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1RAB9AENPP2MAPT | |
| SCHEMBL162044 | 0.76 | ENPP2 (0.46) | SMN1; SMN2ALDH1A1RAB9AENPP2MAPT | |
| SCHEMBL162210 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2RAB9AENPP2GAANPC1 | |
| SCHEMBL9983363 | 0.75 | ALDH1A1 (0.64) | SMN1; SMN2ALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL15034716 | 0.73 | ALDH1A1 (0.61) | SMN1; SMN2ALDH1A1RAB9AGAAMAPT | |
| Hydrochloric Acid SCHEMBL162532 | 0.72 | ALDH1A1 (0.60) | SMN1; SMN2ALDH1A1RAB9AGAAMAPT | |
| SCHEMBL1756326 | 0.72 | RAB9A (0.63) | SMN1; SMN2ALDH1A1RAB9AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2611783-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-07-10 | — | — | EP | disclosed |
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | Piramal Enterprises Limited (IN) | 2013-06-20 | — | — | US | disclosed |
| WO-2012029032-A2 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158075-A1 | HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS | DGAT1, DGAT2, SOAT1 | SMN1; SMN2 2105/4885ALDH1A1 369/4885RAB9A 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.